Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 23;25(8):308.
doi: 10.31083/j.rcm2508308. eCollection 2024 Aug.

Advantages of using Genetically Elevated Lipoprotein(a) Levels in Predicting 5-Year Major Adverse Cardiovascular Events Relating to Coronary Artery Disease in Women

Affiliations

Advantages of using Genetically Elevated Lipoprotein(a) Levels in Predicting 5-Year Major Adverse Cardiovascular Events Relating to Coronary Artery Disease in Women

Aleksandr B Shek et al. Rev Cardiovasc Med. .

Abstract

Background: This study aimed to investigate major adverse cardiovascular events (MACE) in patients with coronary artery disease (CAD) over 5 years, in general, and depending on sex, lipoprotein(a) level, and number of kringle IV type 2 (KIV-2) repeats in the Lipoprotein(A) (LPA) gene.

Methods: This study comprised 216 patients (120 women and 96 men) hospitalized with a diagnosis of "CAD, unstable angina IIB class". The three-point risk of MACEs was assessed over 5 years: cardiovascular death, non-fatal myocardial infarction, and stroke. The number of KIV-2 repeats in the LPA gene was determined by quantitative real-time polymerase chain reaction (qPCR).

Results: The relative risk of MACE in patients with elevated lipoprotein(a) (Lp(a)) was 2.0 (95% CI 1.04-3.87, p < 0.05) for quartile 4 (Q4) 48 mg/dL versus quartile 1 (Q1) 6 mg/dL. This was mainly attributable to an increase in men-relative risk (RR) 2.6 (95% CI 1.10-6.16, p < 0.05)-but not in women: RR 1.4 (95% CI 0.50-3.92). Mean lipoprotein(a) levels were inversely correlated with 42.5 and 7.5 for Q1 and Q4 KIV-2 repeat numbers, respectively. The relative risks of MACE for Q1 vs. Q4 KIV-2 repeats were as follows: 3.0 (95% CI 1.48-6.08, p < 0.001) for all patients; 3.0 (95% CI 1.20-6.55, p < 0.01) for men; 3.3 (95% CI 1.02-10.4, p < 0.05) for women.

Conclusions: Quantifying kringle IV type 2 repeat copy number in the LPA gene using qPCR more accurately reflects the risk of major adverse cardiovascular events within 5 years in women with coronary artery disease.

Keywords: CAD; LPA kringle IV type 2 genetic polymorphism; MACE; lipoprotein(a); qPCR; sex differences.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1.
Fig. 1.
Risk of MACEs by quartiles of lipoprotein(a) (Lp(a)) in all patients (A), and men (B)and women (C) separately. Q1, Q2–3, Q4, quartiles of Lp(a); RR, relative risk; MACE, major adverse cardiovascular event.
Fig. 2.
Fig. 2.
Risk of MACEs by quartiles for 2-Δ⁢Δ⁢𝐂𝐭* (number of KIV-2 repeats) in all patients (A) and men (B) and women (C) separately. Q1, Q2–3, Q4, quartiles of 2-Δ⁢Δ⁢Ct* from quantitative real-time polymerase chain reaction (qPCR), as a genetic score for lipoprotein(a) concentration, associated with apolipoprotein(a) isoform size and LPA KIV-2 number of repeats. RR, relative risk; MACE, major adverse cardiovascular event; KIV-2, kringle IV type 2.

References

    1. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. European Heart Journal . 2010;31:2844–2853. - PMC - PubMed
    1. Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics. Journal of Internal Medicine . 2013;273:6–30. - PubMed
    1. Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) Circulation . 2014;129:635–642. - PMC - PubMed
    1. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA . 2009;301:2331–2339. - PubMed
    1. Langsted A, Kamstrup PR, Nordestgaard BG. High lipoprotein(a) and high risk of mortality. European Heart Journal . 2019;40:2760–2770. - PubMed

LinkOut - more resources